Eisai in-licenses fosravuconazole rights from Sato

Eisai (TYO: 4523) has entered into a license agreement with fellow Japanese drugmaker Sato Pharmaceutical regarding the development and commercialization rights for the antifungal agent fosravuconazole in the Asia/Oceania region.

The accord provides Eisai with exclusive licenses to the intellectual property rights of fosravuconazole in the given countries/regions (10 ASEAN nations, Australia, New Zealand, South Korea, and Taiwan) to Sato Pharma.

Eisai noted that ravuconazole, the active ingredient of fosravuconazole, is an antifungal agent discovered and developed by Company. Fosravuconazole is a prodrug of ravuconazole, which improves its solubility and bioavailability. In Japan, Seren Pharma and Sato Pharma have developed fosravuconazole based on the exclusive rights to develop, commercialize, and sublicense granted by Eisai. The treatment has been marketed by Sato Pharma as the oral antifungal agent Nailin for the indication of “onychomycosis” since July 2018, which Eisai is co-promoting.